Neuphoria Therapeutics (NEUP) Equity Average (2021 - 2026)

Neuphoria Therapeutics (NEUP) has 5 years of Equity Average data on file, last reported at $29.6 million in Q1 2026.

• Quarterly Equity Average rose 48.76% year-over-year to $29.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.6 million (up 48.76% YoY) and the FY2025 annual result came in at $18.2 million, down 7.61% from the prior year.
• Equity Average rose to $29.6 million in Q1 2026 per NEUP's latest filing, from $21.1 million in the prior quarter.
• Across five years, Equity Average topped out at $31.5 million in Q2 2023 and bottomed at $15.4 million in Q4 2024.
• The 4-year median for Equity Average is $19.2 million (2023), against an average of $20.6 million.
• The widest annual swing landed in 2024, when Equity Average tumbled 43.68%; it then jumped 48.76% in 2026.
• Tracing NEUP's Equity Average over 4 years: stood at $18.4 million in 2023, then dropped by 16.08% to $15.4 million in 2024, then surged by 36.97% to $21.1 million in 2025, then surged by 40.07% to $29.6 million in 2026.
• Per Business Quant, the three latest NEUP Equity Average figures stand at $29.6 million (Q1 2026), $21.1 million (Q4 2025), and $15.8 million (Q3 2025).

Peer Comparison